NCT00371033View on ClinicalTrials.gov

Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

PHASE3CompletedINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

April 30, 2008

Conditions
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Interventions
DRUG

Pregabalin

Pregabalin 150 mg/d (50 mg orally 3 times daily) for 2 weeks, then 300 mg/d (100 mg orally 3 times daily) for 2 weeks, and then 600 mg/d (200 mg orally 3 times daily) for 2 weeks.

DRUG

Placebo

Placebo at same frequency as pregabablin

Trial Locations (11)

19140

Temple University School of Medicine, Philadelphia

21201

University of Maryland, Baltimore

39216

University of Mississippi Medical Center, Jackson

44195

Cleveland Clinic Foundation, Cleveland

60611

Northwestern University Feinberg School of Medicine, Chicago

90059

Charles R Drew University of Medicine & Science, Los Angeles

98108

University of Washington Harborview Medical Center, Seattle

90095-1738

David Geffen School of Medicine at UCLA, Los Angeles

94305-5118

Stanford University Medical Center, Stanford

02115

Harvard Medical School, Boston

K7L 2V7

Queen's University, Kingston

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT00371033 - Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) | Biotech Hunter | Biotech Hunter